SCHEMBL2906604

SCHEMBL2906604

CN(C)c1ccc2c[c]oc2c1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
APP P05067 7/20 0.48
TERT O14746 1/20 0.48
SLC16A3 O15427 1/20 0.41
APAF1 O14727 1/20 0.39
USP2 O75604 1/20 0.39
RAB9A P51151 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ALDH1A1 P00352 2/20 0.37
TSHR P16473 2/20 0.37
ALOX15 P16050 1/20 0.37
HSD17B10 Q99714 1/20 0.37
EGFR P00533 2/20 0.36
PGR P06401 4/20 0.36
HTR6 P50406 1/20 0.33
CYP19A1 P11511 1/20 0.33
PSMB5 P28074 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL208143 0.74 CYP1A2 (0.44) APPUSP2RAB9AALDH1A1HSD17B10
SCHEMBL17870639 0.69 CA12 (0.44) RAB9AALDH1A1ALOX15HSD17B10
SCHEMBL207471 0.69 CYP2A6 (0.38) APPALDH1A1
SCHEMBL4148062 0.69 ALDH1A1 (0.41) USP2RAB9AALDH1A1ALOX15HSD17B10
SCHEMBL533212 0.69 AKR1C3 (0.34)
SCHEMBL533400 0.69 ALDH1A1 (0.36) RAB9AL3MBTL1ALDH1A1TSHRALOX15
SCHEMBL533276 0.69 LMNA (0.35) RAB9AALDH1A1ALOX15HSD17B10
SCHEMBL533249 0.69 CYP1A2 (0.44) RAB9AL3MBTL1ALDH1A1ALOX15HSD17B10
SCHEMBL533148 0.69 ALDH1A1 (0.49) APPSLC16A3RAB9AALDH1A1HSD17B10
SCHEMBL12566471 0.69 TERT (0.64) APPTERTSLC16A3APAF1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240209254-A1 OPTICAL ARTICLE, SPECTACLE LENS AND SPECTACLES TOKUYAMA CORPORATION (JP) 2024-06-27 US disclosed
EP-4328636-A1 OPTICAL ARTICLE, SPECTACLE LENS AND SPECTACLES Tokuyama Corporation (JP) 2024-02-28 EP disclosed
EP-2759543-B1 CHROMENE COMPOUND AND CURABLE COMPOSITION TOKUYAMA CORP (JP) 2017-07-19 EP disclosed
US-9588257-B2 Photochromic curable composition TOKUYAMA CORPORATION (JP) 2017-03-07 US disclosed
EP-2669277-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2015-07-01 EP disclosed
EP-2684886-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2015-06-03 EP disclosed
EP-2669278-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2015-05-27 EP disclosed
US-8916071-B2 Chromene compound and curable composition TOKUYAMA CORPORATION (JP) 2014-12-23 US disclosed
EP-2554624-B1 PHOTOCHROMIC CURABLE COMPOSITION TOKUYAMA CORP (JP) 2014-11-05 EP disclosed
US-20140225050-A1 CHROMENE COMPOUND AND CURABLE COMPOSITION TOKUYAMA CORPORATION (JP) 2014-08-14 US disclosed
US-20040094753-A1 Chromene compound TOKUYAMA CORPORATION (JP) 2004-05-20 US disclosed
US-6723859-B2 BASE STRUCTURE IS A CHROMENE(3,2-A)FLUORENE RING CONTAINING SPIRO-FUSED RINGS; PHOTOCHROMIC LENSES; LARGE FADING RATE, LESS COLOR WHEN DETERIORATED, AND EXCELLENT LIGHT RESISTANCE IN THE PHOTOCHROMIC PROPERTIES TOKUYAMA CORPORATION (JP) 2004-04-20 US disclosed
EP-1394156-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2004-03-03 EP disclosed
US-20040014995-A1 Chromene compounds KAWABATA YUICHIRO (JP) 2004-01-22 US disclosed
US-20030096117-A1 Chromene compound TOKUYAMA CORPORATION (JP) 2003-05-22 US disclosed
US-6469076-B1 Chromene compounds TOKUYAMA CORPORATION (JP) 2002-10-22 US disclosed
EP-1054010-B1 Chromene compound TOKUYAMA CORP (JP) 2002-07-24 EP disclosed
US-6340765-B1 PHOTOCHROMIC DYES AND DEVELOPMENT TOKUYAMA CORPORATION (JP) 2002-01-22 US disclosed
EP-1116723-A1 CHROMENE COMPOUNDS TOKUYAMA CORPORATION (JP) 2001-07-18 EP disclosed
EP-1054010-A1 Chromene compound TOKUYAMA CORPORATION (JP) 2000-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014995-A1 Chromene compounds SMARCE1, SMARCB1, SMARCA2 APP 3013/4885TERT 443/4885SLC16A3 4819/4885
US-20140225050-A1 CHROMENE COMPOUND AND CURABLE COMPOSITION CRY2, CRY1, CDYL APP 3110/4885TERT 585/4885SLC16A3 4864/4885
US-20030096117-A1 Chromene compound SMARCE1, SMARCD2, SMARCB1 APP 2680/4885TERT 612/4885SLC16A3 4822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.